Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Friday.
A number of other research analysts also recently issued reports on AQXP. Zacks Investment Research downgraded Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. BidaskClub downgraded Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Finally, Canaccord Genuity set a $22.00 price objective on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $22.25.
Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at 12.85 on Friday. Aquinox Pharmaceuticals has a one year low of $9.83 and a one year high of $19.97. The company’s market capitalization is $301.51 million. The firm has a 50 day moving average price of $14.28 and a 200 day moving average price of $14.77.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its earnings results on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.59). On average, equities research analysts predict that Aquinox Pharmaceuticals will post ($2.15) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://ledgergazette.com/2017/09/17/aquinox-pharmaceuticals-inc-aqxp-rating-lowered-to-sell-at-valuengine.html.
Large investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its stake in shares of Aquinox Pharmaceuticals by 10.0% in the 1st quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after purchasing an additional 11,035 shares during the period. Archon Partners LLC lifted its stake in shares of Aquinox Pharmaceuticals by 44.0% in the 2nd quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock valued at $253,000 after purchasing an additional 5,500 shares during the period. Investment Centers of America Inc. acquired a new position in shares of Aquinox Pharmaceuticals in the 1st quarter valued at about $172,000. Alps Advisors Inc. lifted its stake in shares of Aquinox Pharmaceuticals by 4.7% in the 2nd quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock valued at $297,000 after purchasing an additional 939 shares during the period. Finally, Nexthera Capital LP acquired a new position in shares of Aquinox Pharmaceuticals in the 2nd quarter valued at about $1,276,000. 95.15% of the stock is currently owned by institutional investors.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.